[u'-----BEGIN PRIVACY-ENHANCED MESSAGE-----\nProc-Type: 2001,MIC-CLEAR\nOriginator-Name: webmaster@www.sec.gov\nOriginator-Key-Asymmetric:\n MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen\n TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB\nMIC-Info: RSA-MD5,RSA,\n SCjbxqu1in9zm0TIX826/r/l0CK29QEQ/d9THq/KB3GfQzGzVkvSrPMeOUMIFKcG\n +TzwQb0CvnYgHqt01Q/RhQ==\n\n', u'0000351346-04-000066.txt : 20040917\n', u'0000351346-04-000066.hdr.sgml : 20040917\n', u'20040917104503\nACCESSION NUMBER:\t\t0000351346-04-000066\nCONFORMED SUBMISSION TYPE:\t8-K\nPUBLIC DOCUMENT COUNT:\t\t2\nCONFORMED PERIOD OF REPORT:\t20040917\nITEM INFORMATION:\t\tResults of Operations and Financial Condition\nFILED AS OF DATE:\t\t20040917\nDATE AS OF CHANGE:\t\t20040917\n\nFILER:\n\n\tCOMPANY DATA:\t\n\t\tCOMPANY CONFORMED NAME:\t\t\tBIOMET INC\n\t\tCENTRAL INDEX KEY:\t\t\t0000351346\n\t\tSTANDARD INDUSTRIAL CLASSIFICATION:\tORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]\n\t\tIRS NUMBER:\t\t\t\t351418342\n\t\tSTATE OF INCORPORATION:\t\t\tIN\n\t\tFISCAL YEAR END:\t\t\t0531\n\n\tFILING VALUES:\n\t\tFORM TYPE:\t\t8-K\n\t\tSEC ACT:\t\t1934 Act\n\t\tSEC FILE NUMBER:\t001-15601\n\t\tFILM NUMBER:\t\t041035045\n\n\tBUSINESS ADDRESS:\t\n\t\tSTREET 1:\t\t56 EAST BELL DR\n\t\tCITY:\t\t\tWARSAW\n\t\tSTATE:\t\t\tIN\n\t\tZIP:\t\t\t46582\n\t\tBUSINESS PHONE:\t\t5742676639\n\n\tMAIL ADDRESS:\t\n\t\tSTREET 1:\t\t56 E BELL DRIVE\n\t\tSTREET 2:\t\tP O BOX 587\n\t\tCITY:\t\t\tWARSAW\n\t\tSTATE:\t\t\tIN\n\t\tZIP:\t\t\t46581-0587\n', u'\n', u'\n', u'8-K\n', u'1\n', u'f8k0501.htm\n', u'1ST QTR 8-K\n', u'\n', u'SEC Form 8-K Filed 7/7/2003', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'UNITED STATES', u'\n', u'\n', u'\n', u'\n', u'\n', u'SECURITIES AND EXCHANGE COMMISSION', u'\n', u'\n', u'\n', u'\n', u'\n', u'WASHINGTON, DC\xa0 20549', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'FORM 8-K', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'CURRENT REPORT', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Date of report (Date of earliest event reported): ', u'September 17, 2004', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'BIOMET, INC.', u'\n', u'\n', u'\n', u'\n', u'\n', u'(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Indiana', u'\n', u'\n', u'\n', u'0-12515', u'\n', u'\n', u'\n', u'35-1418342', u'\n', u'\n', u'\n', u'\n', u'\n', u'(State or other jurisdiction of incorporation)', u'\n', u'\n', u'\n', u'\xa0(Commission File Number)\xa0', u'\n', u'\n', u'\n', u'\xa0(IRS Employer Identification No.)\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'56 East Bell Drive', u'\n Warsaw, Indiana 46582', u'\n', u'\n', u'\n', u'\n', u'\n', u'(Address of Principal Executive Offices, including\xa0 Zip Code)', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'(574) 267-6639', u'\n', u'\n', u'\n', u'\n', u'\n', u'(Registrant\u2019s Telephone Number, Including Area Code)', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Not Applicable', u'\n', u'\n', u'\n', u'\n', u'\n', u'(Former Name or Former Address, if Changed Since Last Report)', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the\nregistrant under any of the following provisions:', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'[\xa0 ]\xa0 Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'[\xa0 ]\xa0 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'[\xa0 ]\xa0 Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'[\xa0 ]\xa0 Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\nItem 2.02. Resuls of Operations and Financial Condition.', u'\n', u'\n', u'On September 17, 2004, Biomet, Inc. issued a press release announcing its earnings for the first quarter ended August 31, 2004.\nA copy of the press release is being furnished as Exhibit 99.1 to this report and is incorporated herein by reference.', u'\n', u'\n', u'The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed "filed" for purposes of\nSection 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section.\xa0 The information in\nthis Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, except as shall otherwise be\nexpressly set forth by specific reference in such filing.', u'\n', u'\n', u'Item 9.01. Financial Statement and Exhibits.', u'\n', u'\n', u"Exhibit 99.1\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 Press Release announcing Biomet Inc.'s earnings\nfor the first quarter ended August 31, 2004.", u'\n', u'\n', u'\n', u'\n', u'\n', u'SIGNATURES', u'\n', u'Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on\nits behalf by the undersigned hereunto duly authorized.', u'\n', u'BIOMET, INC.', u'\n', u'\n', u'\n', u'\xa0 /s/ Gregory D. Hartman\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\n\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n\nBy: Gregory D. Hartman', u'\nIts:\xa0 Senior Vice President - Finance', u'\n\xa0\xa0\xa0\xa0 \xa0 (Principal Financial Officer)', u'\n', u'Date: September 17, 2004', u'\n', u'\n', u'\n', u'\n', u'\n', u'EX-99\n', u'2\n', u'fex99501.htm\n', u'PRESS RELEASE\n', u'\n', u'9/11/00 8:41 AM', u'\n', u'\n', u'\n', u'\n', u'\n', u'Warsaw, IN . . . September 17, 2004 . . . (NASDAQ:BMET)', u'\n', u'\n', u'BIOMET ANNOUNCES RECORD FIRST QUARTER RESULTS', u'\n', u'\n', u"Biomet, Inc. today reported record sales and earnings results for its first quarter ended August\n31, 2004.\xa0 Net sales increased 18% to $438,160,000, while operating income decreased 9% to $107,232,000 and increased 19%, as\nadjusted, to $140,254,000.\xa0 Net income decreased 9% to $69,488,000 and increased 19%, as adjusted, to $91,023,000, while\ndiluted earnings per share decreased 10% to $.27 and increased 20%, as adjusted, to $.36 per share.\xa0 The Company's reported\nresults reflect the acquisition of Merck KGaA's interest in the Biomet Merck joint venture on March 19, 2004, as well as the\nacquisition of Interpore International, Inc. on June 18, 2004.\xa0 Adjusted results, which are non-GAAP measures, exclude\nacquisition costs, including inventory step-up and write off of in-process research and development.\xa0 A reconciliation to\ncomparable GAAP measures is included in this press release.\xa0", u'\n', u'\n', u'Dane A. Miller, Ph.D., Biomet\'s President and Chief Executive Officer stated, "We are pleased with\nBiomet\'s first quarter operating results which were led by strong growth in the Company\'s reconstructive, spinal hardware and\northobiologic product lines.\xa0 Continued market acceptance of\xa0\xa0 recently introduced products and minimally-invasive\nknee and hip instruments propelled the growth of the Company\'s reconstructive product lines during the first quarter.\xa0 In the\nimportant domestic market for reconstructive devices, Biomet\'s reconstructive products increased 23% during the first\nquarter.\xa0 Worldwide total hip, knee, extremity and dental reconstructive sales grew 13%, 23%, 17% and 25%, respectively,\nduring the recently completed quarter.\xa0 Additionally, sales of the Company\'s spinal hardware and orthobiologic spinal products\nincreased 132% worldwide during the first quarter as Biomet continues to broaden its line of spinal products and technologies\nthrough the recent acquisition of Interpore International, Inc."', u'\n', u'\n', u'Excluding the impact of foreign currency, which increased first quarter sales by $7 million, net\nsales increased 16% during the first quarter of fiscal year 2005.\xa0 United States and international sales, excluding the\neffects of foreign currency, increased 18% and 14%, respectively, during the first quarter.\xa0 Additionally, excluding the\nimpact of the acquisition of Interpore International, Inc., United States and international sales increased 13% and 12%,\nrespectively.', u'\n', u'\n', u"Reconstructive device sales increased 21% worldwide to $282,482,000 during the first quarter of\nfiscal year 2005.\xa0 On a constant currency basis, worldwide reconstructive device sales increased 18%.\xa0 Knee sales\nincreased 23% worldwide during the first quarter and 27% in the United States.\xa0 Knee sales increased 21% worldwide, constant\ncurrency.\xa0 Biomet's industry-leading knee sales growth continues to be driven by new product introductions in addition to the\nCompany's broad line of total knee systems and minimally-invasive, unicondylar knee systems.\xa0 Additionally, Biomet's\nmicroplasty minimally-invasive total knee instruments continue to receive excellent market acceptance.\xa0\xa0\xa0", u'\n', u'\n', u"During the first quarter, hip sales increased 13% worldwide and 11% in the United\nStates.\xa0\xa0\xa0\xa0\xa0 Excluding the impact of foreign currency, hip sales increased 11% worldwide.\xa0 Biomet's\nM", u'2', u"a 38 metal-on-metal system and the Company's broad line of porous coated stems and revision systems continue to lead\nhip sales growth.\xa0 Revision hip sales in the United States increased 17% during the recently completed quarter.", u'\n', u'\n', u'Extremity sales increased 17% worldwide during the first quarter of fiscal year 2005 and 18% in the\nUnited States.\xa0 On a constant currency basis, extremity sales increased 14% worldwide.\xa0 Sales of dental reconstructive\nimplants increased 25% worldwide and 24% in the United States during the first quarter.\xa0 Worldwide dental reconstructive\nimplant sales increased 23%, constant currency.\xa0 Sales of bone cements and accessories increased 29% worldwide during the\nfirst quarter and 71% in the United States.\xa0 Excluding the effect of foreign currency, sales of bone cements and accessories\nincreased 25% worldwide.\xa0 ', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u"Fixation sales increased 1% to $62,713,000 during the first quarter of fiscal year 2005 and were\nflat worldwide, constant currency.\xa0 Lorenz Surgical's craniomaxillofacial fixation sales increased 8% worldwide and 3% in the\nUnited States during the first quarter.\xa0 Worldwide craniomaxillofacial fixation sales increased 7%, constant currency.\xa0\nSales of electrical stimulation products decreased 1% worldwide and 2% in the United States during the first quarter.\xa0\nExternal fixation sales decreased 2% worldwide during the first quarter and decreased 5% in the United States.\xa0 Excluding the\nimpact of foreign currency, external fixation sales decreased 2% worldwide.\xa0 Internal fixation sales decreased 3% worldwide\nand decreased 10% in the United States during the first quarter.\xa0 On a constant currency basis, worldwide internal fixation\nsales decreased 6% during the first quarter.\xa0", u'\n', u'\xa0', u'\n', u'Spinal product sales increased 39% to $52,909,000 and increased 37% in the United States during the\nfirst quarter of fiscal year 2005.\xa0 Spinal sales increased 39% worldwide, constant currency.\xa0 Domestic sales of spinal\nimplants and orthobiological products for the spine increased 132%, while domestic spinal stimulation sales decreased 1% during the\nfirst quarter.\xa0\xa0\xa0\xa0', u'\n', u'\n', u'Sales of Biomet\'s "other products" increased 9% to $40,056,000 and increased 6% in the United\nStates during the first quarter of fiscal year 2005.\xa0 On a constant currency basis, "other products" sales increased 8%\nworldwide.\xa0 Arthroscopy sales increased 4% worldwide during the quarter and increased 7% in the United States.\xa0 On a\nconstant currency basis, arthroscopy sales increased 3% during the first quarter of fiscal year 2005.\xa0 Softgoods and bracing\nsales were flat worldwide and on a constant currency basis during the quarter, and increased 1% in the United States.', u'\n', u'\n', u'Dr. Miller concluded, "Biomet finished the quarter with strong, momentum in the key reconstructive\nand spinal product categories.\xa0 Consequently, we remain comfortable with the range of analysts\' sales and earnings estimates\nof $433 million to $467 million and $.37 to $.39 per share for the second quarter of fiscal year 2005.', u'\n', u'\n', u"Biomet, Inc and its subsidiaries design, manufacture and market products used primarily by\nmusculoskeletal medical specialists in both surgical and non-surgical therapy.\xa0 The Company's product portfolio encompasses\nreconstructive products, including orthopedic joint replacement devices, bone cements and accessories, and dental reconstructive\nimplants; fixation products, including electrical bone growth stimulators, internal and external orthopedic fixation devices,\ncraniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware\nand orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products.\xa0 Headquartered in\nWarsaw, Indiana, Biomet and its subsidiaries currently distribute products in more than 100 countries.", u'\n', u'\n', u'For further information contact Greg W. Sasso, Vice President, Corporate Development and\nCommunications at (574) 372-1528 or Barbara Goslee, Manager, Corporate Communications at (574) 372-1514.', u'\n', u'\n', u'This press release contains certain statements that are "forward-looking\nstatements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,\nas amended.\xa0 Although the Company believes that the assumptions, on which the forward-looking statements contained herein are\nbased, are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence\nor non-occurrence of future events.\xa0 There can be no assurance that the forward-looking statements contained in this press\nrelease will prove to be accurate.\xa0 Some of the factors that could cause actual results to differ from those contained in\nforward-looking statements made in this press release include the success of the Company\'s principal product lines, the Company\'s\nability to develop and market new products and technologies in a timely manner, government regulation, currency exchange rate\nfluctuations, reimbursements from third party payors, litigation, and other risk factors as set forth from time to time in the\nCompany\'s filings with the SEC.\xa0 The inclusion of a forward-looking statement herein should not be regarded as a\nrepresentation by the Company that the Company\'s objectives will be achieved.\xa0 The Company undertakes no obligation to\npublicly update forward-looking statements, whether as a result of new information, future events or otherwise.', u'\n', u'\n', u"All of Biomet's financial information may be obtained on our website at www.biomet.com or you may\ncontact us by e-mail at investor.relations@biometmail.com.", u'\n', u'\n', u'All trademarks are owned by Biomet, Inc., or one of its subsidiaries.', u'\n', u'\n', u'\n', u'\n', u'BIOMET, INC. - - QUARTERLY RESULTS', u'\n', u'FOR THE QUARTERS ENDED AUGUST 31', u'\n', u'(in thousands, except per share data)', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\n\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'2004', u'\n', u'\n', u'\n', u'Adjustments*', u'\n', u'\n', u'\n', u'As Adjusted*', u'\n', u'\n', u'\n', u'\n', u'2003', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Net Sales', u'\n', u'\n', u'\n', u'$\xa0 438,160', u'\n', u'\n', u'\n', u'$\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 -', u'\n', u'\n', u'\n', u'$\xa0 438,160', u'\n', u'\n', u'\n', u'\n', u'$\xa0 370,319', u'\n', u'\n', u'\n', u'\n', u'\n', u'Cost of Sales', u'\n', u'\n', u'\n', u'\xa0 \xa0\xa0 125,972', u'\n', u'\n', u'\n', u'\xa0\xa0 (7,002) (a)', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 118,970', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 105,618', u'\n', u'\n', u'\n', u'\n', u'\n', u'Gross Profit', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 312,188', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 7,002', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 319,190', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0 264,701', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'S, G, & A', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 160,460', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 160,460', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 132,397', u'\n', u'\n', u'\n', u'\n', u'\n', u'R & D', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 44,496', u'\n', u'\n', u'\n', u'\xa0 (26,020)(b)', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 18,476', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 14,748', u'\n', u'\n', u'\n', u'\n', u'\n', u'Operating Income', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 107,232', u'\n', u'\n', u'\n', u'\xa0\xa0 33,022', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 140,254', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 117,556', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Other Income (Expense), Net', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0 (728)', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 -', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0 (728)', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0 3,021', u'\n', u'\n', u'\n', u'\n', u'\n', u'Income Before Taxes And Minority Interest', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 106,504', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 33,022', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 139,526', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 120,577', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Income Taxes', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 37,016', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 11,487(c)', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0 48,503', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 41,979', u'\n', u'\n', u'\n', u'\n', u'\n', u'Income Before Minority Interest', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 69,488', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 21,535', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0 91,023', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 78,598', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Minority Interest', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 -', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 -', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\n- -', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0 2,120', u'\n', u'\n', u'\n', u'\n', u'\n', u'Net Income', u'\n', u'\n', u'\n', u'\xa0 $\xa0\xa0 69,488', u'\n', u'\n', u'\n', u'$\xa0\xa0 21,535', u'\n', u'\n', u'\n', u'\xa0 $\xa0\xa0\xa0\xa0 91,023', u'\n', u'\n', u'\n', u'\n', u'$\xa0\xa0\xa0\xa0 76,478', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Earnings per Share', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Basic', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 .27', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 .09', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 .36', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 .30', u'\n', u'\n', u'\n', u'\n', u'\n', u'Diluted', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 .27', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 .09', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 .36', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 .30', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Basic Shares Outstanding', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 253,856', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 253,856', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 256,847', u'\n', u'\n', u'\n', u'\n', u'\n', u'Diluted Shares Outstanding', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 255,950', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 255,950', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 258,282', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'U.S. sales', u'\n', u'\n', u'\n', u'$\xa0 296,304', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'$\xa0 252,095', u'\n', u'\n', u'\n', u'\n', u'\n', u'Foreign sales', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 141,856', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 118,224', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Reconstructive sales', u'\n', u'\n', u'\n', u'$\xa0 282,482', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'$\xa0 233,439', u'\n', u'\n', u'\n', u'\n', u'\n', u'Fixation sales', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 62,713', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 62,133', u'\n', u'\n', u'\n', u'\n', u'\n', u'Spinal products', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 52,909', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 37,967', u'\n', u'\n', u'\n', u'\n', u'\n', u'Other product sales', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 40,056', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0 36,780', u'\n', u'\n', u'\n', u'\n', u'\n', u'(a)\xa0\xa0 Current period impact of inventory step-up related to the acquisition of the\ninterest of Merck KGaA in the Biomet Merck joint venture and Interpore International, Inc.', u'\n', u'(b)\xa0\xa0 In-process research and development written off as of the closing date related to\nthe acquisition of Interpore International, Inc.', u'\n', u'(c)\xa0\xa0 Tax effect of item a and b above.', u'\n', u'\n', u'*We have included these adjusted measures to provide management and investors with a better\nunderstanding of our results, because expenses related to these acquisitions in the current quarter and the remainder of fiscal\nyear 2005 are not indicative of our future operating results.', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Consolidated Balance Sheets', u'\n', u'\n', u'\n', u'August 31, 2004', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'May 31, 2004', u'\n', u'\n', u'\n', u'\n', u'\n', u'Assets', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0 Cash and Investments', u'\n', u'\n', u'\n', u'$\xa0 158,618', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'$\xa0 235,612', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0 Accounts and notes receivable, net', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 449,436', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 465,949', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0 Inventories', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 424,997', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 389,391', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0 Other current assets', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 116,055', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 91,256', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0 Fixed Assets, net', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 283,573', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 268,826', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0 Goodwill', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 453,179', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 266,860', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0 Other Assets', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 108,042', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 69,803', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0 Total Assets', u'\n', u'\n', u'\n', u'$1,993,900', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'$1,787,697', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u"Liabilities and Stockholders' Equity", u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0 Current Liabilities', u'\n', u'\n', u'\n', u'$\xa0\xa0 537,995', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'$\xa0 313,402', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0 Other Liabilities', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 38,188', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0 26,085', u'\n', u'\n', u'\n', u'\n', u'\n', u"\xa0 Stockholders' Equity", u'\n', u'\n', u'\n', u'\xa0 1,417,717\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0 1,448,210', u'\n', u'\n', u'\n', u'\n', u'\n', u"\xa0\xa0\xa0 Total Liabilities and Stockholders' Equity", u'\n', u'\n', u'\n', u'$1,993,900', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'$1,787,697', u'\n', u'\n', u'\n', u'\n', u'\n', u'The above balance sheet includes the preliminary purchase price allocation in connection with the\nInterpore acquisition.\xa0 The Company believes that changes, if any, when the purchase price allocation is finalized, will not\nbe material.', u'\n', u'\n', u'* * *', u'\n', u'\n', u'\n', u'\n', u'\n-----END PRIVACY-ENHANCED MESSAGE-----\n']